FI961037A0 - Formulations for providing osteogenic proteins - Google Patents

Formulations for providing osteogenic proteins

Info

Publication number
FI961037A0
FI961037A0 FI961037A FI961037A FI961037A0 FI 961037 A0 FI961037 A0 FI 961037A0 FI 961037 A FI961037 A FI 961037A FI 961037 A FI961037 A FI 961037A FI 961037 A0 FI961037 A0 FI 961037A0
Authority
FI
Finland
Prior art keywords
formulations
osteogenic proteins
disclosed
osteogenic protein
providing
Prior art date
Application number
FI961037A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI961037A (en
Inventor
Kalvin W K Yim
Michael C Huberty
Jr Richard P Northey
Richard A Kenley
Jay A Schrier
Jennifer L Smith
John J Steckert
C Michael Philbrook
Patrick Joseph Desouza
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of FI961037A publication Critical patent/FI961037A/en
Publication of FI961037A0 publication Critical patent/FI961037A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/84—Bones; tendons; teeth; cartilage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A composition is disclosed comprising a pharmaceutically acceptable admixture of an osteogenic protein; a porous particulate polymer matrix; an osteogenic protein-sequestering amount of blood clot; and a calcium sulfate hemihydrate-containing substance. Also disclosed are formulations of bone morphogenetic proteins with improved solubility and/or stability characteristics.
FI961037A 1993-09-10 1996-03-06 Formulations for providing osteogenic proteins FI961037A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/119,772 US5385887A (en) 1993-09-10 1993-09-10 Formulations for delivery of osteogenic proteins
PCT/US1994/009870 WO1995007108A2 (en) 1993-09-10 1994-09-02 Formulations for delivery of osteogenic proteins

Publications (2)

Publication Number Publication Date
FI961037A FI961037A (en) 1996-03-06
FI961037A0 true FI961037A0 (en) 1996-03-06

Family

ID=22386293

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961037A FI961037A0 (en) 1993-09-10 1996-03-06 Formulations for providing osteogenic proteins

Country Status (14)

Country Link
US (1) US5385887A (en)
EP (1) EP0724459B1 (en)
JP (1) JPH09502368A (en)
KR (1) KR100329408B1 (en)
AT (1) ATE238819T1 (en)
AU (1) AU695374B2 (en)
CA (1) CA2169362C (en)
DE (1) DE69432596T2 (en)
DK (1) DK0724459T3 (en)
ES (1) ES2196033T3 (en)
FI (1) FI961037A0 (en)
NO (1) NO960905D0 (en)
PT (1) PT724459E (en)
WO (1) WO1995007108A2 (en)

Families Citing this family (184)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1734895A (en) * 1994-03-08 1995-09-25 Genetics Institute Inc. Methods and compositions for treatment of periodontal disease and repair of periodontal lesions
US5626861A (en) * 1994-04-01 1997-05-06 Massachusetts Institute Of Technology Polymeric-hydroxyapatite bone composite
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US5674292A (en) * 1995-06-07 1997-10-07 Stryker Corporation Terminally sterilized osteogenic devices and preparation thereof
NZ503548A (en) * 1996-02-09 2001-09-28 Amgen Inc A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus
EP0852951A1 (en) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stable lyophilized monoclonal or polyclonal antibodies containing pharmaceuticals
ZA9711580B (en) * 1996-12-25 1999-09-23 Hoechst Marion Roussel Ltd Process for the production of purified dimeric bone morphogenetic factors.
EP0957943B2 (en) * 1997-02-07 2008-11-26 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
AU779278B2 (en) * 1997-02-07 2005-01-13 Stryker Corporation Matrix-free osteogenic devices, implants and methods of use thereof
US7041641B2 (en) * 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US20010016646A1 (en) 1998-03-20 2001-08-23 David C. Rueger Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
AU7260598A (en) * 1997-04-28 1998-11-24 Trustees Of The University Of Pennsylvania, The Method for promoting myogenesis using osteogenic proteins
US6391336B1 (en) 1997-09-22 2002-05-21 Royer Biomedical, Inc. Inorganic-polymer complexes for the controlled release of compounds including medicinals
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) * 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
MXPA01003538A (en) * 1998-10-06 2005-09-08 Rush Presbyterian St Luke Method for the treatment of chemonucleolysis.
DE19906096A1 (en) 1999-02-13 2000-08-17 Walter Sebald Protein with a heparin-binding epitope
US7371408B1 (en) * 1999-06-07 2008-05-13 Wright Medical Technology, Inc. Bone graft substitute composition
US7052856B2 (en) * 1999-10-05 2006-05-30 The Regents Of The University Of California NELL-1 enhanced bone mineralization
US20090060988A1 (en) * 1999-10-05 2009-03-05 Kang Ting Nell-1 enhanced bone mineralization
US7884066B2 (en) * 1999-10-05 2011-02-08 The Regents Of The University Of California NELL-1 enhanced bone mineralization
WO2004024893A2 (en) * 2002-09-13 2004-03-25 The Regents Of The University Of California Nell-1 enhanced bone mineralization
US7687462B2 (en) * 1999-10-05 2010-03-30 The Regents Of The University Of California Composition for promoting cartilage formation or repair comprising a nell gene product and method of treating cartilage-related conditions using such composition
EP1155704A1 (en) * 2000-01-13 2001-11-21 Chih-I Lin Orthopedic filling material and method of use thereof
US6630153B2 (en) * 2001-02-23 2003-10-07 Smith & Nephew, Inc. Manufacture of bone graft substitutes
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
SE517168C2 (en) * 2000-07-17 2002-04-23 Bone Support Ab A composition for an injectable bone mineral replacement material
US20080233165A1 (en) * 2000-08-07 2008-09-25 Biolok International, Inc. Time release calcium sulfate and growth factor matrix for bone augmentation
BR0115772A (en) 2000-11-29 2004-01-13 Oculex Pharm Inc Processes for reducing or preventing eye transplant rejection and intraocular implants for use in transplantation
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6949251B2 (en) * 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
US20020169066A1 (en) * 2001-04-16 2002-11-14 Cerabio, L.L.C. Dense porous structures for use as bone substitutes
US20060263401A1 (en) * 2001-07-13 2006-11-23 Flow Focusing, Inc. Formulation and Method for Preventing Infection
US20050129732A1 (en) * 2001-07-13 2005-06-16 Flow Focusing, Inc. Biodegradable, antibiotic, controlled release tape
US20070254009A1 (en) * 2001-07-13 2007-11-01 Flow Focusing, Inc. Antibiotic/bone morphogenic protein formulation and method of treatment
US20070254008A1 (en) * 2001-07-13 2007-11-01 Flow Focusing, Inc. Antibiotic formulation and method of treatment
US7371409B2 (en) * 2001-09-06 2008-05-13 Wright Medical Technology, Inc. Bone graft substitute composition
DK1448246T4 (en) * 2001-11-19 2015-12-21 Scil Technology Gmbh Homogeneously coated device with osteoinductive and osteoconductive properties
WO2003066000A2 (en) * 2002-02-08 2003-08-14 Wyeth Formulation comprising bioactive agents and method of using same
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003258172B2 (en) 2002-03-29 2008-02-28 Wright Medical Technolgy, Inc. Bone graft substitute composition
US6652887B1 (en) 2002-06-24 2003-11-25 Wright Medical Technology, Inc. Bone graft substitute composition
US7291179B2 (en) * 2002-06-24 2007-11-06 Wright Medical Technology, Inc. Bone graft substitute composition
US20040002770A1 (en) * 2002-06-28 2004-01-01 King Richard S. Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
US7029006B2 (en) * 2002-08-29 2006-04-18 Canon Kabushiki Kaisha Sheet feeding apparatus and image forming apparatus
US8986737B2 (en) * 2002-09-05 2015-03-24 Wm. Marsh Rice University Antibiotic microspheres for treatment and prevention of osteomyelitis and enhancement of bone regrowth
CN100522241C (en) * 2002-09-10 2009-08-05 Scil技术股份有限公司 Metal implant coated under reduced oxygen concentration with osteoinductive protein
AU2003286472A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2006516639A (en) * 2003-02-01 2006-07-06 ニユーララブ・リミテツド Active immunization to generate antibodies against soluble A-beta
US7507257B2 (en) * 2003-02-04 2009-03-24 Wright Medical Technology, Inc. Injectable resorbable bone graft material, powder for forming same and methods relating thereto for treating bone defects
EP1594889B1 (en) * 2003-02-07 2011-04-06 The Regents of The University of California Nell peptide expression systems and bone formation activity of nell peptide
PE20050627A1 (en) * 2003-05-30 2005-08-10 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
CA2529503A1 (en) * 2003-06-20 2004-12-29 Royer Biomedical, Inc. Drug polymer complexes
US20040262809A1 (en) * 2003-06-30 2004-12-30 Smith Todd S. Crosslinked polymeric composite for orthopaedic implants
EP1677735B1 (en) 2003-10-17 2014-07-23 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US8328876B2 (en) 2003-12-31 2012-12-11 Warsaw Orthopedic, Inc. Bone matrix compositions and methods
US20070231788A1 (en) * 2003-12-31 2007-10-04 Keyvan Behnam Method for In Vitro Assay of Demineralized Bone Matrix
US8734525B2 (en) 2003-12-31 2014-05-27 Warsaw Orthopedic, Inc. Osteoinductive demineralized cancellous bone
JP2007518804A (en) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド Composition for topical ophthalmic treatment preferably containing triamcinolone acetonide and hyaluronic acid
US8377904B2 (en) * 2004-02-09 2013-02-19 Hill's Pet Nutrition, Inc. Composition and method for use in cartilage affecting conditions
US7691607B2 (en) * 2004-02-09 2010-04-06 The Regents Of The University Of California Expression system of NELL peptide
EP2409707B8 (en) * 2004-04-15 2015-05-06 Alkermes Pharma Ireland Limited Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
BRPI0510485A (en) 2004-04-30 2007-11-13 Allergan Inc biodegradable intravitreal tyrosine kinase inhibitor implants
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US7384430B2 (en) * 2004-06-30 2008-06-10 Depuy Products, Inc. Low crystalline polymeric material for orthopaedic implants and an associated method
BRPI0513243B8 (en) * 2004-07-12 2021-05-25 Allergan Inc ophthalmic compositions and their uses
EP3508201A3 (en) * 2004-08-09 2019-10-16 Enrique Melendez Hevia Glycine as a diet supplement for use in the treatment skin problems that result from underlying collagen disorders and and cosmetic uses thereof
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US7250550B2 (en) * 2004-10-22 2007-07-31 Wright Medical Technology, Inc. Synthetic bone substitute material
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
JP2008523815A (en) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド Humanized amyloid beta antibody for use in improving cognition
PE20061152A1 (en) * 2004-12-15 2006-10-13 Neuralab Ltd HUMANIZED ANTIBODIES THAT RECOGNIZE THE BETA AMYLOID PEPTIDE
US7883653B2 (en) 2004-12-30 2011-02-08 Depuy Products, Inc. Method of making an implantable orthopaedic bearing
US7896921B2 (en) * 2004-12-30 2011-03-01 Depuy Products, Inc. Orthopaedic bearing and method for making the same
US7879275B2 (en) * 2004-12-30 2011-02-01 Depuy Products, Inc. Orthopaedic bearing and method for making the same
SV2008002394A (en) * 2005-01-28 2008-02-08 Wyeth Corp POLYPEPTIDE STABILIZED LIQUID FORMULATIONS REF. AHN- 072SV
GT200600031A (en) * 2005-01-28 2006-08-29 ANTI-BETA ANTIBODY FORMULATION
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP1851237A4 (en) 2005-02-16 2009-01-07 Univ California Pharmaceutical compositions for treating or preventing bone conditions
EP1855732A1 (en) * 2005-02-24 2007-11-21 Roland Dricot Bone implant
WO2006130690A2 (en) 2005-06-01 2006-12-07 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US20060286171A1 (en) * 2005-06-17 2006-12-21 Tianhong Zhou Bone morphogenetic protein formulations
US7754246B2 (en) 2005-09-09 2010-07-13 Wright Medical Technology, Inc. Composite bone graft substitute cement and articles produced therefrom
US8025903B2 (en) 2005-09-09 2011-09-27 Wright Medical Technology, Inc. Composite bone graft substitute cement and articles produced therefrom
ES2393756T3 (en) * 2005-11-01 2012-12-27 Warsaw Orthopedic, Inc. Methods to produce bone matrix compositions
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US8784810B2 (en) * 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2007136664A2 (en) * 2006-05-16 2007-11-29 Flow Focusing, Inc. Antibiotic formulation and method of treatment
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8197840B2 (en) * 2006-07-21 2012-06-12 Genera Istrazivanja D.O.O. Whole blood-derived coagulum device for treating bone defects
EP2046361A4 (en) * 2006-07-26 2011-06-29 Univ California Osteogenic enhancer composition
US20080051796A1 (en) * 2006-08-01 2008-02-28 Warsaw Orthopedic, Inc. Graft retention tack
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
DE102006060958A1 (en) * 2006-12-20 2008-06-26 Jennissen, Herbert P., Prof. Dr. Process for the preparation of a polymer matrix, implants made thereof and their use
CA2680365A1 (en) * 2007-03-22 2008-10-02 Alkermes, Inc. Coacervation process
JP2011526240A (en) * 2007-04-18 2011-10-06 ヤンセン アルツハイマー イミュノセラピー Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) * 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2144624A1 (en) * 2007-05-15 2010-01-20 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
WO2008157497A2 (en) * 2007-06-15 2008-12-24 Osteotech, Inc. Method of treating tissue
WO2008157495A2 (en) 2007-06-15 2008-12-24 Osteotech, Inc. Bone matrix compositions and methods
US9554920B2 (en) * 2007-06-15 2017-01-31 Warsaw Orthopedic, Inc. Bone matrix compositions having nanoscale textured surfaces
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US20110054408A1 (en) * 2007-07-10 2011-03-03 Guobao Wei Delivery systems, devices, tools, and methods of use
WO2009009684A1 (en) * 2007-07-10 2009-01-15 Osteotech, Inc. Delivery system
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
US8058237B2 (en) * 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
JO3076B1 (en) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
WO2009052492A2 (en) * 2007-10-19 2009-04-23 Osteotech, Inc. Demineralized bone matrix compositions and methods
DE102007051914A1 (en) * 2007-10-29 2009-05-07 Herbert Prof. Dr. Jennissen Process for the preparation of particles loaded with growth factors and the particles thus obtained
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2276458A1 (en) * 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Liquid buffered gdf-5 formulations
US9616153B2 (en) * 2008-04-17 2017-04-11 Warsaw Orthopedic, Inc. Rigid bone graft substitute
CA2725208A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US9492375B2 (en) * 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010093955A1 (en) * 2009-02-12 2010-08-19 Osteotech,Inc. Segmented delivery system
WO2010138637A2 (en) 2009-05-26 2010-12-02 The Regents Of The University Of California Fibromodulin peptide
CN104323981B (en) 2009-09-28 2019-03-12 精达制药公司 The quick foundation and/or termination of basic steady-state drug delivery
US20120322882A1 (en) 2009-11-09 2012-12-20 Allergan, Inc. Compositions And Methods For Stimulating Hair Growth
JP5669050B2 (en) * 2010-01-15 2015-02-12 国立大学法人島根大学 Bone cement
US9180137B2 (en) 2010-02-09 2015-11-10 Bone Support Ab Preparation of bone cement compositions
US9358323B2 (en) * 2010-04-29 2016-06-07 Warsaw Orthopedic, Inc. Flowable ceramic putty
CA2798710C (en) 2010-05-11 2019-08-27 Venkat R. Garigapati Organophosphorous, multivalent metal compounds, & polymer adhesive interpenetrating network compositions & methods
EP2606121B1 (en) 2010-08-19 2016-05-11 The Regents of The University of California Compositions comrpising perivascular stem cells and nell-1 protein
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
AU2012243410B8 (en) 2011-04-11 2016-11-17 Red Rock Regeneration Inc. System and method for multiphasic release of growth factors
WO2012158527A2 (en) 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
CN104220046A (en) 2012-04-11 2014-12-17 感应生物制品股份有限公司 System and method for multiphasic release of growth factors
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
DK2958603T3 (en) 2013-02-20 2018-07-16 Bone Support Ab IMPROVED CURE FOR HARDWARE BONE COMPENSATION
TWI651103B (en) 2013-12-13 2019-02-21 萊特醫技股份有限公司 Multiphase bone graft replacement material
RS59285B1 (en) 2014-03-20 2019-10-31 Stayble Therapeutics Ab A composition for use in the treatment of intervertebral disc-related pain
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3240563B1 (en) * 2014-12-29 2020-12-09 Bioventus LLC Systems and methods for improved delivery of osteoinductive molecules in bone repair
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
CN108601864A (en) 2015-10-30 2018-09-28 佰欧维恩图斯有限责任公司 Matrix for enhancing the delivering of self-bone grafting molecule in Bone Defect Repari
MX2018014016A (en) 2016-05-16 2019-08-01 Intarcia Therapeutics Inc Glucagon-receptor selective polypeptides and methods of use thereof.
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN109310801A (en) 2016-06-10 2019-02-05 佰欧维恩图斯有限责任公司 Use the protein delivery of porous metal structure
CN110225762A (en) 2017-01-03 2019-09-10 因塔西亚制药公司 The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent
US11103618B2 (en) 2018-02-22 2021-08-31 Warsaw Orthopedic, Inc. Demineralized bone matrix having improved handling characteristics

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2093348B (en) * 1981-02-23 1984-09-12 Leo Pharm Prod Ltd Pharmaceutical composition for implantation
BR8406921A (en) * 1983-05-31 1985-06-04 Choong Gook Jang DRY COMPRESSION COMPOSITES, DIRECT FOR CONTROLLED RELEASE DOSAGE FORMS
US4526909A (en) * 1984-01-09 1985-07-02 Regents Of The University Of California Polymethylmethacrylate delivery system for bone morphogenetic protein
US4619655A (en) * 1984-01-26 1986-10-28 University Of North Carolina Plaster of Paris as a bioresorbable scaffold in implants for bone repair
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
IL83003A (en) * 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5108436A (en) * 1988-09-29 1992-04-28 Collagen Corporation Implant fixation
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
AU5950790A (en) * 1989-06-30 1991-01-17 United States Gypsum Company Calcium sulfate hemihydrate composition having utility in the presence of blood
US5290558A (en) * 1989-09-21 1994-03-01 Osteotech, Inc. Flowable demineralized bone powder composition and its use in bone repair
WO1993000050A1 (en) * 1991-06-21 1993-01-07 Genetics Institute, Inc. Pharmaceutical formulations of osteogenic proteins
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
CA2119090A1 (en) * 1993-03-26 1994-09-27 Wayne R. Gombotz Compositions for controlled release of biologically active tgf-.beta.

Also Published As

Publication number Publication date
PT724459E (en) 2003-08-29
FI961037A (en) 1996-03-06
CA2169362C (en) 2000-05-02
DE69432596T2 (en) 2004-03-18
NO960905L (en) 1996-03-06
NO960905D0 (en) 1996-03-06
AU695374B2 (en) 1998-08-13
DK0724459T3 (en) 2003-10-27
EP0724459B1 (en) 2003-05-02
WO1995007108A3 (en) 1995-06-15
ES2196033T3 (en) 2003-12-16
KR100329408B1 (en) 2002-09-26
KR960704587A (en) 1996-10-09
WO1995007108A2 (en) 1995-03-16
EP0724459A1 (en) 1996-08-07
DE69432596D1 (en) 2003-06-05
ATE238819T1 (en) 2003-05-15
JPH09502368A (en) 1997-03-11
AU7953794A (en) 1995-03-27
US5385887A (en) 1995-01-31

Similar Documents

Publication Publication Date Title
FI961037A0 (en) Formulations for providing osteogenic proteins
GR3033204T3 (en) Formulations of blood clot-polymer matrix for delivery of osteogenic proteins.
DE69118535D1 (en) OSTEO-INDUCTIVE PHARMACEUTICAL FORMULATIONS
ATE142693T1 (en) PREPARATION OF VASCULAR ENDOTHELIAL CELL GROWTH FACTOR
ATE81785T1 (en) TRICALCIUM PHOSPHATE FOR IMPLANTATION MATERIALS.
DE69104777D1 (en) Oral drug forms of biologically active proteins.
ATE243254T1 (en) BIOSYNTHETIC BONE-FORMING PROTEINS AND BONE-FORMING DEVICES CONTAINING THEM
DK0591392T3 (en) Pharmaceutical formulations of osteogenic proteins
ATE103932T1 (en) FUSION PROTEIN CONSISTING OF GM-CSF AND IL-3.
DE3687402D1 (en) THROMBINE COMPOSITION.
DE69008423D1 (en) Dynamic fixation of porcine acid valves.
HUT72325A (en) Stabile, liophylised composition containing proteins and kit applicabe for dosing
DE60016614D1 (en) COMPOSITIONS FOR THE DELIVERY OF OSTEOGENIC PROTEINS
DE3856557D1 (en) Acyldeoxyribonucleoside derivatives and uses thereof
DE69520475D1 (en) Pharmaceutical composition of biologically active peptides or proteins
HUP9900506A2 (en) Prothrombin derivatives
ATE281155T1 (en) DRUG ADMINISTRATION OF PROTEINS FROM POLYMER MIXTURES
NO981864L (en) Upl ° sningsmetoder
ATE188129T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING IPRIFLAVONE AND THEIR USE FOR REPLACING BONE DEFECTS
FI902700A0 (en) VAEVNADPLASMINOGENAKTIVATORDERIVAT.
UA29770A (en) Method for inhibition of human immunodeficient virus reproduction